A Phase 1 Study of LY2801653 in Patients With Advanced Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 27 Sep 2017
At a glance
- Drugs Merestinib (Primary) ; Cetuximab; Cisplatin
- Indications Adenocarcinoma; Cholangiocarcinoma; Colorectal cancer; Head and neck cancer; Solid tumours; Squamous cell cancer; Uveal melanoma
- Focus Adverse reactions
- Sponsors Eli Lilly
- 21 Sep 2017 Planned End Date changed from 17 May 2018 to 17 Oct 2018.
- 21 Sep 2017 Planned primary completion date changed from 17 May 2018 to 17 Oct 2018.
- 06 Sep 2017 Status changed from recruiting to active, no longer recruiting.